Introduction {#S0001}
============

Based on American Cancer Society (2012), lung cancer occurs when a healthy cell in the lung undergoes changes and transforms into the cancer cell and starts to multiply and grows out of control in one or both lungs. This causes the formation of tumour and inefficiency of its function as the lungs provide oxygen to the body via the blood. The total cancer cases reported were 1.6 million cases (13%) from overall global prevalence, and 1.4 million (18%) cancer-related deaths worldwide is lung cancer.[@CIT0001] The long-term survival rate for the advanced stage of lung cancer is five-year (less than 10%) even with advanced medical science field.[@CIT0002] Current treatments used to treat lung cancer such as surgery, radiation therapy and chemotherapy-targeted therapy are reported. The combination of treatment was also applied to treat cancer depending on the size of a tumour. For example, a combination of chemotherapy and radiation therapies which use a therapeutic agent to inhibit the cancer cell. Many therapeutic agents were used for lung cancer treatment. For example, cisplatin, doxorubicin, quercetin, curcumin and gemcitabine.[@CIT0003]--[@CIT0005]

Gemcitabine (GEM) has been used as chemotherapeutics drug for various solid tumours such as lung cancer, pancreatic cancer, breast cancer, bladder cancer and colon cancer[@CIT0006],[@CIT0007] which approved by Food and Drug Administration (FDA). GEM has been used in the first line treatment and has excellent therapeutic activity (median overall survival was three months with gemcitabine) in chemotherapy for non-small cell lung cancer (NSCLC).[@CIT0005],[@CIT0008],[@CIT0009] However, it has very short half-life which is 8--17 min in human plasma and 9 min murine plasma,[@CIT0009],[@CIT0010] which unfavourable pharmacokinetic and pharmacodynamics profiles as well as poor penetration in the complex environment of lung cancer.[@CIT0002] Due to the hydrophilic nature of GEM, it is difficult to pass through plasma membrane passively (Wang et al, 2016). Most of the studies on human used higher dosage (1000--1250 mg/m^2^, 2 to 3 times for 3 weeks) to achieve therapeutic drug level by intravenous infusion.[@CIT0005],[@CIT0011]--[@CIT0013] To overcome these problems, a delivery system needs to be developed in order to enhance GEM to pass through the plasma membrane.

A pulmonary delivery route is a potential approach towards enhancing the efficiency of treatment with lower toxicity effect towards the normal cell. Pulmonary delivery by inhalation shows good potential for lung cancer as it provides some advantages which do not pass through the first-pass metabolism, fewer side effects of systemic and better compliance to patients as free needle approach.[@CIT0004],[@CIT0013],[@CIT0014] The particle size of molecules is essential in order to deliver the drug to the targeted cells. The particles between 10 and 20 nm in size deposited to the alveolar region are about four times more efficient than those several microns in diameter.[@CIT0015] The smaller the particles are, the more efficient the delivery, It could be however depending on the delivery system used. For example, the effect of the size of liposome to deliver the drug via inhalation had been studied by Garbuzenko et al (2014).[@CIT0016] The results showed that lung concentration of 600 nm and 200 nm liposomes at 3 and 24 h after inhalation was almost 4.5 and 23 times higher when compared with one h (both had practically identical distribution profile).

Nanoemulsion is an emulsion system where they have a particle size less than 200 nm and consist of oil, surfactant and water with an isotropic appearance.[@CIT0018],[@CIT0019] Nanoemulsion system showed compliance towards the requirement for pulmonary delivery administration. For example, docetaxel-loaded nanoemulsion has been reported with high inhibition (50% reduction of A549 when exposed to 76.41 μg/mL) of the lung cancer cell.[@CIT0003] From the literature, nanoemulsion does not prolong the half-life of GEM, but it provides shelf-life and long-term stability to arrive at the targeted area and also for storage.[@CIT0020] As general, nanoemulsion protection the drug from degradation and UV light.[@CIT0020],[@CIT0021] Other advantages of nanoemulsion include ease of preparation, the stability of thermodynamic and increase of surface area due to fine particle size.[@CIT0022] Nanoemulsions have the potential to deliver active compounds to the lungs as they provide high drug loading efficiency (1.5 mg/mL of budesonide; 0.05% of quercetin in nanoemulsion).[@CIT0004],[@CIT0023] Furthermore, they can improve pulmonary deposition and retention leads to prolongment of periods in the lung tissues.[@CIT0024] Thus, in this study, gemcitabine-loaded nanoemulsion formulation was formulated and optimized for lung cancer treatment. The physicochemical characteristics of the optimized nanoemulsion were investigated. This was followed by the release of in vitro drug and the evaluation of cytotoxicity of the optimized nanoemulsion

Materials and methods {#S0002}
=====================

Materials {#S0002-S2001}
---------

Gemcitabine (GEM, purity \>90%) was purchased from Sigma-Aldrich (Germany). Polysorbate 80 (Tween 80), sorbitan mono-laurate 80 (Span 80) and sodium chloride (NaCl) were purchased from Merck (Germany). Methanol (95%) and acetonitrile (HPLC grade, 99%) were obtained from J.T. Baker Chemical (USA). Medium-chain triglyceride (MCT) was purchased from Gattefosse Sas (France). The human lung fibroblast (MRC5) and human lung cancer carcinoma cell line (A549) was purchased from American Type Culture Collection (ATCC, USA). The deionised water was prepared using Mili-Q filtration system, EMD MiIlipore (Billerica, MA, USA).

Constructions of the ternary phase diagram {#S0002-S2002}
------------------------------------------

NaCl solution was prepared by dissolving 0.9 g of NaCl into 100 mL of deionised water. GEM (0.15 g) was dissolved in 14.85 g of NaCl solution. Tween 80 and Span 80 were mixed at ratio 1:1. The mixed surfactants and medium chain triglyceride (MCT) were weighed at various ratios ranging from 0:100 to 100:0. Then, the mixture with a total weight of 0.5000 g was placed into a 10 mL screw-cap glass tube (total of 11 tubes) and was vortexed using a vortex mixer (VM-300, Gemmy Industrial CORP-Taiwan). The mixture was centrifuged at 4000 rpm using a Hettich centrifuge (Model EBA, Germany) for 15 min at room temperature. GEM mixture (dissolved in NaCl solution) (1%, w/w) was then added into the eleven test tubes separately and were vortexed for homogenised. The samples were centrifuged at 4000 rpm for 15 min and then observed by the naked eyes for identification of physical phase appearance. The transparent/translucent appearance sample was considered as isotropic, L~t~, while milky until separation layers formed was regarded as a multilayer, M. The steps were repeated with the addition of 10, 20, 30, 40 until 90% w/w of gemcitabine solution. These methods were repeated for different surfactant ratios (Tween 80: Span80) of 3:7 and 3:2 with the HLB values were 7.51 and 10.75, respectively. The ternary phase diagrams were constructed using a CHEMIX School v3.6 software (UK).

Preparation of nanoemulsion containing gemcitabine {#S0002-S2003}
--------------------------------------------------

The combination of high energy and low energy emulsification techniques were used to prepare nanoemulsion. GEM was dissolved in NaCl solution. The mixture was mixed with a mixed surfactant (Tween 80 and Span 80) at room temperature to form an aqueous phase. MCT was sonicated (10 min), heated at 60 °C and stirred using a magnetic bar at 200 rpm for 10 min and homogenised using high shear homogeniser at 6000 rpm for 3 min. MCT was added dropwise into a beaker containing an aqueous phase. The mixture was then homogenised again at 300 rpm for 4 h using overhead stirrer (IKA@ RW 20 Digital, Nara, Japan).

Experimental design {#S0002-S2004}
-------------------

The composition of nanoemulsion formulation was optimized by using D-optimal mixture design. Design-Expert, Version 7.1.5 (Stat-Ease Inc., Minneapolis, USA) was used to analyse the results statically. While the lower and higher limit of the independent variables were determined from the ternary phase diagram. The composition limits of the formulation were listed in [Table 1](#T0001){ref-type="table"}. The independent variables of NaCl solution, GEM, MCT and mixed surfactant (Tween 80: Span 80) were utilised to study the effect of a response variable, particle size. The interactions between independent variables and response were plotted and shown in three-dimensional (3D) surface graphs. Table 1The limit of independent variables compositionsSymbolVariablesRange (% w/w)LowerHighASodium chloride solution (NaCl solution)2.803.00BGemcitabine (GEM)0.020.04CTween 80: Span 80 (T80:S80, (at ratio 3:7))15.0018.00DMedium chain triglyceride (MCT)78.9682.18

The study of the significant difference between the independent variables was carried out by analysis of variance (ANOVA) and R^2^ (coefficient of determination). The criteria of the good reduced model with high correlation, *p*-value significant (*p*\<0.0500) and R^2^ value higher than 0.900 were evaluated.

Verification of the model {#S0002-S2005}
-------------------------

Several random formulations were prepared and then compared quantitatively on the response variable by calculating their residual standard error (RSE, %) using the equation shown in [Equation 1](#M0001). RSE values lower than 5 % was also in agreement with the predicted values.[@CIT0025] $$\documentclass[12pt]{minimal}
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Physicochemical characterisation of the optimized nanoemulsion {#S0002-S2006}
--------------------------------------------------------------

### Particle size and polydispersity index measurement {#S0002-S2006-S3001}

The particle size and polydispersity index (PDI) of the nanoemulsion were measured by using Zetasizer Nano ZS (Malvern Instrument Ltd., UK) at 25 °C. The measurement was performed using a dynamic light scattering technique with a scattering angle of 173°. The samples were diluted with MCT (1:500) and injected into the sample cell. The intensity distribution was used for the measurement of the mean average (z-average) particle size. The measurement was repeated in triplicate.

### Zeta potential measurement {#S0002-S2006-S3002}

Zeta potential of the optimized nanoemulsion was measured by using Zetasizer Nano ZS (Malvern Instrument Ltd., UK) at 25 °C. The calculation of their zeta potential was based on their electrophoretic mobility of dispersed particles in a charged field. The stability of nanoemulsion improved as it had zeta potential values higher than +30 mV or lower than -- 30 mV.[@CIT0026] The samples were diluted with MCT (1:500). The measurement was repeated in triplicate.

### Transmission electron microscopy analysis {#S0002-S2006-S3003}

The morphology of the optimized nanoemulsion was visualised using a Transmission Electron Microscope (TEM). The sample was diluted with deionised water and dropped into a 300-mesh formvar-coated copper grid (left at 25 °C for 3 mins) and negatively stained using 2% w/w phosphotungstic acid (left at 25 °C for 5 mins). Meanwhile, the excess liquid was removed with a piece of Whatman filter paper and dried at room temperature. The samples were observed with Hitachi H-700 TEM (Japan) while the acquired digital images were processed with Adobe Photoshop^®^ software.

### Drug loading efficiency {#S0002-S2006-S3004}

The efficiency of GEM loaded in optimized nanoemulsion was determined by the ultrafiltration method. The Centrisart tube (molecular weight cut-off 10,000 Da, Sartorious, AG, Germany) was used to separate the aqueous phase and oil phase. It consists of a floater and centrifugal tube. Optimized nanoemulsion was placed in a floater and centrifuged at 4000 rpm for 15 min. aqueous phase was passed through floater through the filter while the oil phase remained in the floater. Both phases were measured using high performance liquid chromatography (HPLC) measurement (Waters Corporation, Milford, MA) which was equipped with Phenomenex reverse phase C18 column (Gemini, LC column C18, 5µm, 250×4.6 mm) and UV/Vis detector (Waters 2489, Waters Corporation, Milford, MA) at wavelength 269 nm. The [Eq 2](#M0002) below was used to determine the drug loading efficiency: $$\documentclass[12pt]{minimal}
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where W~initial~ is the amount of drug present and W~obtained~ in the concentration from oil phase of the optimized nanoemulsion.

### Stability study {#S0002-S2006-S3005}

Centrifugation test was used whereby the fresh sample was centrifuged at 4000 rpm for 15 mins, and any precipitated formed was observed. The storage stability against particle size was evaluated in three different temperatures (4, 25 and 45 °C). The instability mechanisms of the particle size were analysed by coalescence and Ostwald ripening analysis. Coalescence is the process of thinning and disruption of the liquid film between the droplets with the result of the fusion of two or more droplets into larger ones.[@CIT0017] Coalescence rate can be analysed by plotting the changes in particle size over time. All data obtained from the storage stability of those three different temperatures were applied in the [Equation 3](#M0003). $$\documentclass[12pt]{minimal}
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Where r is the average radius of particle size after a certain time, ω is the frequency of rupture per unit of the film surface, while r⁰ is the value at time t=0. A graph of (1/r^2^, nm^−2^) against time (seconds) was plotted. Ostwald ripening is the increment of the particle size due to the diffusion of the oil phase through the aqueous phase. Ostwald ripening rate can be determined using Lifshitz--Slesov--Wagner theory, as shown in [Eq 4](#M0004). $$\documentclass[12pt]{minimal}
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Where, *ω* is the frequency of rupture per unit surface of the film, r is the average radius of the droplets over time, *t* is the storage time in seconds, *C (∞)* is the bulk phase solubility, Vm is the molar volume of the internal phase, D is the diffusion coefficient of the dispersed phase in the continuous phase, *ρ* is the density of the dispersed phase, R is the gas constant, and T is the absolute temperature. Graph of radii (r^3^, nm^3^) against storage time (t, seconds) at different temperatures were plotted and compared.

### In vitro permeation study {#S0002-S2006-S3006}

The drug release was determined using by Franz diffusion cells method as it mimicked the air-liquid interface present in the lung.[@CIT0027],[@CIT0028] Cellulose acetate membrane (13 mm, 0.64 cm^2^, 0.45 µm) was clamped between two compartments (donor and receptor compartments) and clipped tightly to prevent leakage. The receptor compartment was filled with 5 mL of phosphate buffer saline (PBS) at pH 7.4. The PBS was sunk at condition temperature of 37±2 °C of temperature along with process studies (48 hrs) and stirred at a speed of 600 rpm for 48 hrs. The optimized nanoemulsion formulation (0.2 mL, C~0~=800 µg) was put on the top of the donor compartment. At regular time intervals, 0.5 mL of sample was withdrawn from the receptor compartment and immediately replaced with fresh PBS to maintain the same condition. The samples were kept in the fridge (4 °C) to preserve GEM. These procedures were repeated by replacing PBS with sodium dihydrogen phosphate buffer (PB) at pH 6.5. These procedures have been studied in order to correlate the effect of pH towards the drug release.

A high-performance liquid chromatography (HPLC) measurement (Waters Corporation, Milford, MA) was equipped with Phenomenex reverse phase C18 column (Gemini, LC column C18, 5 µm, 250×4.6 mm) and UV/Vis detector (Waters 2489, Waters Corporation, Milford, MA). The mobile phase used to analyse GEM release at pH 7.4 was the ratio of phosphate buffer saline and acetonitrile (PBS: ACN, 93:7) at flow rate 1 mL/min at wavelength 269 nm and ambient temperature. The concentration of GEM released was determined based on the standard curve of known GEM with concentration range 20--1000 µg/mL (R^2^=0.9907). These methods were repeated by replacing mobile phase PBS with PB (PB: ACN, 93:7) to analyse GEM release at pH 6.5. The concentration of GEM released was determined based on the standard curve of known GEM with concentration range 20--1000 µg/mL (R^2^=0.9974). All experiments were carried out in triplicate.

### Kinetic measurement {#S0002-S2006-S3007}

The kinetic measurement of GEM release from optimized nanoemulsion was determined by the mathematical models, zeroth- order (cumulative amount of drug release against time, [Eq 5](#M0005)), first-order (log cumulative amount of drug remaining against time, [Equation 6](#M0006)), Higuchi (cumulative percentage of drug release against square root of time, [Eq 7](#M0007)), Hixson-Crowell (cube root cumulative amount of drug remaining against time, [Eq 8](#M0008)) and Korsmeyer-Peppas (log cumulative percentage of drug release against log time, Eq 9).[@CIT0004] The best model fitted the release data was evaluated based on the coefficient determination (R^2^) obtained from plotted graph. The models were constructed based on the model's theoretical equation. $$\documentclass[12pt]{minimal}
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$${M^0}$$
\end{document}$ is the initial amount of GEM in dissolution media, M~t~ the amount of GEM released in time, $\documentclass[12pt]{minimal}
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### Cytotoxicity studies of the optimized nanoemulsion {#S0002-S2006-S3008}

MTT assay (3- \[4, 5- dimethylthiazol-2-yl\]-2, 5-diphenyltetrazolium bromide) on human lung fibroblast (MRC5) and human lung cancer carcinoma cell line (A549) was used to determine cytotoxicity. The concentration of 2×103 cells/mL of cell culture was prepared and plated onto 96-well plates (100 mL/well). The diluted ranges concentrations (500, 200, 100, 50, 20, 1 μg/mL) of control (GEM solution) were added to each well and it was incubated for 48 and 72 h. MTT solution was added by the end of incubation samples to the cells and continued for incubation in an incubator for 3 h and was replicated in triplicate. After purple formazan crystals solubilised completely in dimethyl sulfoxide (DMSO), the optical density (OD) of the samples was measured using an ELISA reader at a wavelength of 570 nm. The percentage of cell viability was determined using [Eq 10](#M0010). $$\documentclass[12pt]{minimal}
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Graphs were plotted with the percentage of cell viability against their respective concentrations. This method was repeated by replacing the control with nanoemulsion without GEM and optimized nanoemulsion.

Statistical analysis {#S0002-S2007}
--------------------

The statistical analyses of the experiments were performed using analysis of variance (ANOVA) which are  Type I *t*-test (least significant different, LSD) and Duncan's Multiple Range Test by using SAS 9.4 software. The value of *p*\<0.05 was considered significant. All experiments were carried out triplicate. The error bars represent the mean values with standard deviation (SD) unless otherwise indicated.

Results and discussion {#S0003}
======================

Phase behaviour of mct/surfactants/nacl system {#S0003-S2001}
----------------------------------------------

The aqueous phases used to construct ternary phase diagram was sodium chloride solution (0.9 %) with a various ratio of the surfactant of Tween 80 and Span 80 (1:1, 3:2, 3:7) which indicated different HLB values (9.65, 10.75 and 7.51, respectively).

[Figure 1A](#F0001){ref-type="fig"}--[C](#F0001){ref-type="fig"}, they show isotropic region obtained at maximum 14% of GEM in NaCl solution. Those three of phase diagram gave different amount of percentage area of isotropic ([Figure 1A](#F0001){ref-type="fig"} = 13%, [Figure 1B](#F0001){ref-type="fig"}= 15%, [Figure 1C](#F0001){ref-type="fig"} =16%) and minimum usage of surfactant to form isotropic ([Figure 1A](#F0001){ref-type="fig"} = 25%, [Figure 1B](#F0001){ref-type="fig"} =20%, [Figure 1C](#F0001){ref-type="fig"} = 10%). [Figure 1C](#F0001){ref-type="fig"} has 7.51 of HLB value, which is higher lipophilicity and tends to dissolve in oil (MCT). Thus the least amount of mixed surfactant (10%) can form isotropic formulation. While [Figure 1A](#F0001){ref-type="fig"} and [B](#F0001){ref-type="fig"} have higher HLB value (9.65, 10.75); they are more hydrophilic and dissolve more in water.

The F1 in [Figure 1C](#F0001){ref-type="fig"} (T80: S80 ratio at 3.7) was chosen for optimization of the nanoemulsion formulation containing GEM, as it shows the lower percentages of surfactant in the isotropic region. The higher amount of surfactant used can cause cytotoxicity towards the normal cell. Thus the minimum amount should be used.[@CIT0029],[@CIT0030] The composition was showed as in [Table 2](#T0002){ref-type="table"}. Figure 1The ternary phase diagrams of MCT/surfactant/NaCl: GEM systems at different Tween 80: Span 80, T80:S80 ratios; (**A**) 1:1 (**B**) 3:2 (**C**) 3:7. Li = Isotropic phase and M = multiple phase. Table 2The composition of the selected point for MCT/surfactants/NaCl systemComposition\
(% w/w)Sodium chloride (NaCl)0.0398Water1.9602Gemcitabine (GEM)0.0300T80: S8018.0000Medium-chain triglyceride (MCT)79.0036[^1]

Optimization of the nanoemulsion formulation containing GEM {#S0003-S2002}
-----------------------------------------------------------

The effects of four independent variables on the actual and predicted particle size of nanoemulsion values were shown in [Table 3](#T0003){ref-type="table"}. The evaluation of the coefficient significance of models was determined by the analysis of variance (ANOVA), as shown in [Table 4](#T0004){ref-type="table"}. The *F-*values and *p*-value of this model were 47.2694 and \<0.0001 respectively. These results showed significant to the particle size. In this model, the R^2^, adjusted R^2^ and standard deviation of the reduced model are 0.9822, 0.9614 and ±1.89, respectively. The Eq 11 for the model describing the particle size obtained from the model can be written as: $$\documentclass[12pt]{minimal}
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\end{document}$$ Table 3The predicted and actual particle size values of nanoemulsionsABCDParticle size, nmActualPredicted12.8000.02016.50080.680124.800124.80022.9000.03016.50080.570149.900149.90032.8000.04018.00079.160138.800138.80043.0000.02018.00078.980130.200130.20052.8000.04018.00079.160132.800132.80062.9000.04015.00082.060155.800155.80072.9000.03018.00079.070157.100157.10083.0000.04018.00078.960154.800154.80092.9000.02016.50080.580138.00138.000102.9000.03016.50080.570149.800149.800112.9500.03517.25079.765152.800152.800123.0000.02015.00081.980130.000130.000132.9000.02517.25079.825146.500146.500143.0000.03016.50080.470134.900134.900152.8000.03015.00082.170128.500128.500162.9000.03016.50080.570149.400149.400172.8500.02515.75081.375135.900135.900182.8000.02018.00079.180132.600132.600192.9500.02515.75081.275134.300134.300[^2] Table 4The analysis of variance (ANOVA) for the modelSourceMeans square*F*-value*p*-valueModel168.806847.2694\<0.0001Linear mixture72.074020.18220.0015Residual3.5711\--Lack of fit1.09560.18120.9028Pure error6.046667\--

D-optimal design analysis {#S0003-S2003}
-------------------------

[Figure 2(A](#F0002){ref-type="fig"}) shows that as the NaCl solution increased, the particle size increased. This phenomenon happened because of the higher presence of ions from NaCl solution which is known as electrolytes. The presence of electrolytes could lower the attractive forces between water droplets which decrease dielectric constant of the aqueous phase and reduce collision frequency, hence stabilised the droplets[@CIT0031],[@CIT0032] which also increase of particle size. As for [Figure 2(B](#F0002){ref-type="fig"}), the particle size decreased as the surfactant (T80: S80) increased which leads to reduce the interfacial tension and reduction of Laplace pressure and stress.[@CIT0004],[@CIT0033],[@CIT0034] Figure 2(**A**) The contour plot of two-dimensional plot and three-dimensional surfaces with a constant amount of surfactant (T80: S80 (C)), showing the interaction effect between three variables (NaCl solution (**A**), GEM (B), MCT (D)). (**B**) The contour plot of two-dimensional plot and three-dimensional surfaces with a constant amount of oil (MCT (D)), showing the interaction effect of three variables (NaCl solution (A), GEM (B), T80: S80 (C)).

Based on [Table 5](#T0005){ref-type="table"}, the composition of the validation set used where the actual particle size and predicted particle size showed agreement as their RSE of five set validations were below 2.72%, which indicated that the model was fitted to the system. Table 5Validation set and optimized nanoemulsionABCDParticle sizePDIZeta potential mVResidual standard error (%)ActualPredictedValidationV13.000.0416.4680.50155.60±0.04153.440.101--1.41V23.000.0415.4681.50148.40±0.03146.660.176--1.19V33.000.0415.9681.00153.90±0.30158.210.254--2.72V42.900.0317.0080.07150.00±0.10151.890.169--1.24V52.900.0317.5079.57152.30±0.18154.190.042--1.23Optimization3.000.0415.0081.96141.57±0.05143.540.168−37.101.37[^3]

The predicted value of particle size for optimized nanoemulsion was 143.54 nm while the actual value was 141.57±0.05 nm with RSE of 1.37%.

Physiochemical characterisation of the optimized nanoemulsion {#S0003-S2004}
-------------------------------------------------------------

The particle size distribution of the optimized nanoemulsion containing GEM obtained was 141.57±0.05 nm, which valid with predicted value (143.54 nm) as its RSE is 1.37%. The polydispersity index (PDI) of 0.168 was obtained, which indicated a monodisperse system and zeta potential value of −37.10 mV. [Figure 3](#F0003){ref-type="fig"} showed that the optimized nanoemulsion was spherical. The particles were distributed uniformly without aggregation among them, and the particle size obtained agreed with particle size analysis. While the drug loaded in optimized nanoemulsion is 100%. Figure 3Morphology of the optimized nanoemulsion at 100 nm of magnification.

Stability study {#S0003-S2005}
---------------

The stability study by centrifugation test and storage stability, have shown that optimized nanoemulsion was stable. A fresh sample of optimized nanoemulsion remained as a homogeneous mixture after centrifuged at 4000 rpm for 15 min, which indicated that it was stable under normal storage condition. For storage stability of three different temperatures, optimized nanoemulsion remained at homogeneous phase after 90 days, as shown in [Table 6](#T0006){ref-type="table"}. Table 6Physical stability of optimized nanoemulsion containing GEMTemperature (°C)Stability storage (days)Centrifugation test1721306090√4√√√√√√25√√√√√√45√√√√√√[^4]

There were increments in particle size after storage for (90 days) which were 51.31% (4 °C), 53.32% (25 °C) and 63.79% (45 °C) as in [Figure 4](#F0004){ref-type="fig"}. The plotted graphs ([Figs. 5](#F0005){ref-type="fig"} and [6](#F0006){ref-type="fig"}) show no linear relationship, indicating the increment of particle size over time happened not because of coalescence rate and Ostwald ripening phenomena. Coalescence rate analysis included the linear relationship between 1/r^2^ against storage time in which two droplets fusion formed larger particles as rupture of continuous phase films happened.[@CIT0038],[@CIT0039] Ostwald ripening was a process expansion of particles in the nanoemulsion system due to curvature effects by absorbing energy from the surrounding.[@CIT0017],[@CIT0035],[@CIT0036] Particles in the nanoemulsion system gained energy from the surrounding temperature. The higher energy increased the kinetic energy of particles and the efficient collision among particles (Brownian law). Thus, the diffusion that happened led to the increment of particle size. Figure 4Stability of the optimized nanoemulsion against time. Figure 5Coalescence rate analysis. Figure 6Ostwald ripening analysis.

In vitro permeation study {#S0003-S2006}
-------------------------

The in vitro permeation study of optimized nanoemulsion at different pH (pH 7.4 and 6.5) have been studied. [Figure 7](#F0007){ref-type="fig"} showed that the release of GEM at pH 7.4 (13.62%) was lower (3-fold) compared to the drug released at pH 6.5 (45.19%) for 48 hrs. In other words, the release of GEM increased significantly with reductions in pH, which similar results were reported by Lee et al (2014).[@CIT0042] These results indicated the optimized nanoemulsion had a sustained property of release at pH 7.4 (pH value normal lung cell) and an unstained property release at pH 6.5 (pH value lung cancer cell). In addition, the presence of non-ionic polyoxyethylene sorbitan esters (Tween 80 and Span 80), which were to stabilise the emulsion by lowering the surface tension between particles and preventing the coalescence phenomena cause GEM to be retained in nanoemulsion.[@CIT0037] Figure 7Graph cumulative percentage release GEM, %.

Kinetic release analysis {#S0003-S2007}
------------------------

The coefficient of determination (R^2^) of all kinetic models for GEM release from optimized nanoemulsion in pH 7.4 and pH 6.5 were shown in [Table 7](#T0007){ref-type="table"}. All plotted graph shows linear relationships to a different degree of time for pH 7.4 and pH 6.5 ([Figure 8](#F0008){ref-type="fig"} and [Figure 9](#F0009){ref-type="fig"}). The highest R^2^ for pH 7.4 was zeroth order (0.9932) followed by first- order (0.9930), Hixson-Crowell (0.9931), Higuchi (0.9756) and Korsmeyers-Peppas (0.9673). While the highest R^2^ for pH 6.5 was zeroth-order (0.9957) followed by Hixson-Crowell (0.9909), Higuchi (0.9874), first-order (0.9870) and Korsmeyers-Peppas (0.9632). The R^2^ for GEM release from optimized nanoemulsion in pH 7.4 and pH 6.5 were fitted the most with zeroth-order. Figure 8Graph of kinetic models, zeroth-order (**A**) first-order (**B**), Hixson-Crowell (**C**), Higuchi (**D**) and Korsmeyers-Peppas (**E**) for GEM release from optimized nanoemulsion in pH 7.4. Figure 9Graph of kinetic models, zeroth-order (**A**) first-order (**B**), Hixson-Crowell (**C**), Higuchi (**D**) and Korsmeyers-Peppas (**E**) for GEM release from optimized nanoemulsion in pH 6.5.Table 7The coefficient of determination (R^2^) of all kinetic models for GEM release from optimized nanoemulsion in pH 7.4 and pH 6.5pH 7.4pH 6.5Kinetic modelCoefficient of determination (R^2^)Zeroth- order0.99320.9957First- order0.99300.9870Hixson-Crowell0.99310.9909Higuchi0.97560.9874Korsmeyer- peppas0.96730.9632

Cytotoxicity study {#S0003-S2008}
------------------

The cytotoxicity of GEM, nanoemulsion without GEM and optimized nanoemulsion were investigated by MTT assay for 72 hrs on MRC5 and A549 cells. The selection of the cell lines was actually based on the previous study[@CIT0004],[@CIT0038] [Figure 10A](#F0010){ref-type="fig"} and [B](#F0010){ref-type="fig"} show the percentage of cell viability of GEM, nanoemulsion without GEM and optimized nanoemulsion when exposed to MRC5 and A549 at concentration 100 to 500 µg/mL. The IC~50~ of GEM, nanoemulsion without GEM and optimized nanoemulsion were listed in [Table 8](#T0008){ref-type="table"}.Table 8IC~50~ values for cytotoxicity studyIC~50~ μg/mLMRC5A549GEM70Highly toxic up to 1Nanoemulsion without GEM110Not toxic up to 500Optimized nanoemulsion16555

GEM exposure at concentration 50 µg/mL and 100 µg/mL induces a statistically significant (*p*\<0.010) decreased (49.607% and 50.392%) of the cell viability. The percentage of cell viability decrease as the concentration of GEM increase (1--500 µg/mL). While a statistically significant (*p*\<0.050) of reduction of the percentage of cell viability as the increased concentration (100--500 µg/mL). The IC~50~ of GEM exposure on MRC5 and A549 are 70 µg/mL and highly toxic up to the identified concentrations (1 µg/mL).

The nanoemulsion without GEM shows a statistically significant (*p*\<0.050) decrease more than 50% percentage cell viability when exposed on MRC5 at concentration 200 µg/mL and 500 µg/mL. The exposure of it on A549 does not induce of the cell viability up to 500 µg/mL. The IC~50~ for nanoemulsion without GEM was at 110 µg/mL for MRC5 and not toxic to A549 cell up to 500 µg/mL.

When optimized nanoemulsion exposure to MRC5 at concentration 100 µg/mL and 200 µg/mL induce a statistically significant (*p*\<0.050) reduction (48.282% and 55.588%) of cell viability. The optimized nanoemulsion induced cytotoxic response with IC~50~ at 165 µg/mL (MRC5) and 55 µg/mL (A549). Besides, the optimized nanoemulsion shows the reduction of percentage cell viability due to the increase of sample concentration ([Figure 10B](#F0010){ref-type="fig"}). These results of the studies demonstrated that optimized nanoemulsion had the capability to induce cytotoxicity on A549 lung cancer cells.

Based on [Figure 10](#F0010){ref-type="fig"}, there show optimized nanoemulsion shows of reduction of cell viability when it introduced to MRC5 cell and A549 cell because of the presence of GEM. GEM was activated their cytotoxicity activity through the series of phosphorylation intercellularly by deoxycytidine kinase to the monophosphate and the by pyrimidine nucleoside monophosphate kinase to give gemcitabine diphosphate which derives gemcitabine triphosphate by nucleoside diphosphate kinase.[@CIT0008],[@CIT0039],[@CIT0040] The gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme that produces the deoxyribonucleotides for DNA synthesis in S phase of dividing cells while gemcitabine triphosphate intermediate into DNA which terminated DNA synthesis.[@CIT0041] Thus, MRC5 and A549 cells reduced up to 50% at certain concentration when they were introduced to optimized nanoemulsion. Figure 10The cytotoxicity effect of different cell lines: (**A**) MRC5 lung cells, (**B**) A549 lung cancer cells at 72 h treatment.

Conclusion {#S0004}
==========

Nanoemulsions containing gemcitabine have been developed by a combination of high and low energy emulsification technique. Based on ternary phase diagrams constructed, the selected formulation was successfully optimized by D-optimal design. The optimized nanoemulsion was obtained with good physical stability against centrifugation test and storage temperatures. The in vitro permeation study obtained 3-fold released towards pH value of lung cancer compare pH value of normal lung cell. Cytotoxicity studies of the optimized nanoemulsion showed that it was toxic to A549 lung cancer cell but less cytotoxicity when compared to GEM only toward lung cancer cell, A549. While on MRC5 normal lung cell, optimized nanoemulsion also less toxic compared to GEM only. These results of studies show optimized nanoemulsion by nanoemulsion system has the potential to enhance the treatment for lung cancer.
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[^1]: **Abbreviations:** T80: S80, Tween 80 and Span 80 (at ratio 3:7).

[^2]: **Abbreviations:** A, Gemcitabine; B, NaCl solution; C, Tween 80 and Span 80(at ratio 3:7); D, medium chain triglycerides.

[^3]: **Abbreviations:** A, Gemcitabine; B, NaCl solution; C, Tween 80 and Span 80 (at ratio 3:7); D, medium chain triglycerides.

[^4]: **Note:** √ No separation.
